In July 2010, GlaxoSmithKline, maker of Paxil, reportedly settled approximately 800 lawsuits alleging Paxil birth defects for around $1 billion. The lawsuits reportedly alleged that Paxil caused birth defects in babies who were exposed to the antidepressant before their birth. At the time, The Wall Street Journal (7/20/10) quoted an e-mail from GlaxoSmithKline as saying the company "has reached an agreement to settle certain cases involving the use of Paxil during pregnancy. The details of those settlements are confidential. Other cases remain pending."
One such pending case was that of Anna Blyth, whose lawsuit alleged that she (now 14 years old) was born with cardiac birth defects that were caused by her mother's use of Paxil while pregnant. The lawsuit alleged that GlaxoSmithKline failed to warn that the use of Paxil could result in birth defects. Anna was born with a narrowing of her aorta.
GlaxoSmithKline defended itself, saying it acted responsibly in studying Paxil and marketing the antidepressant for use. The company also argued that Anna did not suffer any long-term negative effects from her heart problems.
The judge in that case dismissed the lawsuit halfway through the trial.
READ MORE PAXIL LEGAL NEWS
Persistent pulmonary hypertension of the newborn (previously called primary pulmonary hypertension of the newborn), is a life-threatening condition in which the baby's circulatory system does not properly adapt to breathing on its own. The result is that blood does not properly reach the lungs, which prevents oxygenated blood from being circulated throughout the baby's body.
Symptoms of PPHN include rapid breathing, rapid heart rate, low oxygen levels and respiratory distress.
Paxil is an antidepressant in a class of drugs known as selective serotonin reuptake inhibitors (SSRIs).